vs
Side-by-side financial comparison of Bitcoin Depot Inc. (BTM) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $162.5M, roughly 1.7× Bitcoin Depot Inc.). Bitcoin Depot Inc. runs the higher net margin — 3.4% vs -45.7%, a 49.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 20.1%). Bitcoin Depot Inc. produced more free cash flow last quarter ($2.5M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -4.9%).
Bitcoin Depot Inc. is one of the largest cryptocurrency ATM operators across North America. It provides retail consumers with accessible in-person kiosks to buy and sell Bitcoin and other leading digital assets, alongside online crypto purchase services via bank transfer. Its self-service kiosks are located in high-traffic retail spaces including grocery stores, gas stations and convenience stores.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BTM vs GH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $162.5M | $281.3M |
| Net Profit | $5.5M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 7.3% | -43.0% |
| Net Margin | 3.4% | -45.7% |
| Revenue YoY | 20.1% | 39.4% |
| Net Profit YoY | 690.4% | -15.8% |
| EPS (diluted) | $0.08 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | $162.5M | $265.2M | ||
| Q2 25 | $172.1M | $232.1M | ||
| Q1 25 | $164.2M | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | $135.3M | $191.5M | ||
| Q2 24 | $163.1M | $177.2M | ||
| Q1 24 | $138.5M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $5.5M | $-92.7M | ||
| Q2 25 | $6.1M | $-99.9M | ||
| Q1 25 | $4.2M | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-939.0K | $-107.8M | ||
| Q2 24 | $-2.6M | $-102.6M | ||
| Q1 24 | $-1.5M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | 7.3% | -37.3% | ||
| Q2 25 | 9.2% | -45.9% | ||
| Q1 25 | 10.8% | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | 4.1% | -61.3% | ||
| Q2 24 | 4.7% | -56.8% | ||
| Q1 24 | 0.5% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | 3.4% | -35.0% | ||
| Q2 25 | 3.5% | -43.0% | ||
| Q1 25 | 2.6% | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -0.7% | -56.3% | ||
| Q2 24 | -1.6% | -57.9% | ||
| Q1 24 | -1.1% | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $0.08 | $-0.74 | ||
| Q2 25 | $0.16 | $-0.80 | ||
| Q1 25 | $0.20 | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | $-0.05 | $-0.88 | ||
| Q2 24 | $-0.13 | $-0.84 | ||
| Q1 24 | $-0.25 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $59.3M | $378.2M |
| Total DebtLower is stronger | $67.5M | $1.5B |
| Stockholders' EquityBook value | $21.0M | $-99.3M |
| Total Assets | $125.3M | $2.0B |
| Debt / EquityLower = less leverage | 3.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | $59.3M | $580.0M | ||
| Q2 25 | $48.0M | $629.1M | ||
| Q1 25 | $35.0M | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | $32.2M | $585.0M | ||
| Q2 24 | $43.9M | $933.7M | ||
| Q1 24 | $42.2M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $67.5M | $1.1B | ||
| Q2 25 | $66.5M | $1.1B | ||
| Q1 25 | $56.2M | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $44.5M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $37.6M | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $21.0M | $-354.5M | ||
| Q2 25 | $4.7M | $-305.5M | ||
| Q1 25 | $-4.6M | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | $-7.9M | $-60.1M | ||
| Q2 24 | $4.4M | $-1.6M | ||
| Q1 24 | $5.0M | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $125.3M | $1.3B | ||
| Q2 25 | $109.1M | $1.3B | ||
| Q1 25 | $89.7M | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $87.4M | $1.5B | ||
| Q2 24 | $97.5M | $1.6B | ||
| Q1 24 | $90.1M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | 3.21× | — | ||
| Q2 25 | 14.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 9.27× | — | ||
| Q1 24 | 7.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $2.5M | $-54.2M |
| FCF MarginFCF / Revenue | 1.6% | -19.3% |
| Capex IntensityCapex / Revenue | 2.5% | 9.9% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.1M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $6.6M | $-35.4M | ||
| Q2 25 | $10.2M | $-60.3M | ||
| Q1 25 | $16.3M | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | $5.8M | $-51.1M | ||
| Q2 24 | $10.1M | $-94.0M | ||
| Q1 24 | $1.3M | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $2.5M | $-45.8M | ||
| Q2 25 | $9.8M | $-65.9M | ||
| Q1 25 | $15.9M | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | $-1.0M | $-55.3M | ||
| Q2 24 | $7.6M | $-99.1M | ||
| Q1 24 | $789.0K | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | 1.6% | -17.3% | ||
| Q2 25 | 5.7% | -28.4% | ||
| Q1 25 | 9.7% | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | -0.8% | -28.9% | ||
| Q2 24 | 4.7% | -55.9% | ||
| Q1 24 | 0.6% | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 2.5% | 3.9% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | 5.0% | 2.2% | ||
| Q2 24 | 1.5% | 2.9% | ||
| Q1 24 | 0.4% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.67× | — | ||
| Q1 25 | 3.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTM
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
